• Emergent BioSolutions Inc., of Rockville, Md., said it started a Phase II study of TRU-016 in combination with bendamustine in patients with relapsed chronic lymphocytic leukemia, triggering a $6 million milestone payment to Emergent by Abbott, of Abbot Park, Ill. The study is designed to compare the combination of the anti-DC37 monospecific protein therapeutic plus bendamustine to bendamustine alone in about 100 randomized patients, with a primary endpoint of overall response rate defined by 2008 International Workshop on Chronic Lymphocytic Leukemia criteria.